MedTrace Logo

Mitigating Chronic Respiratory Disease Through the Lens of Multimorbidity (MARES3)

NCT07134855 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 473

Last updated 2025-08-21

No results posted yet for this study

Summary

The investigators aim to investigate how individuals attending primary healthcare (PHC) services in Brazil for treatment of non-communicable diseases (NCDs), identified there as having abnormal spirometry or as being at high risk for lung health problems (such as asthma and chronic obstructive pulmonary disease-COPD, collectively referred to as chronic respiratory disease (CRDs)) using the COLA-6 questionnaire, are able to access diagnostic testing and treatment.

The investigators will re-assess people diagnosed with abnormal spirometry in the MARES1 study (NCT07050823) or identified as being at high-risk for CRDs in the MARES2 study (NCT07093021). The estimated sample size is 309 from MARES1 and 164 from MARES2 for a total sample size of 473.

Qualitative interviews will be conducted with a diverse subsample of 30 participants to explore their experience accessing CRD diagnosis and treatment, including barriers and facilitators, while all participants will undergo basic data collection and spirometry.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Preserved Ratio Impaired Spirometry (PRISM)

Sponsors & Collaborators

  • Universidade Federal de Sao Carlos

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • John R Hurst, PhD FRCP · University College London Hospitals

  • Renata G Mendes, DFisio · Federal University of Sao Carlos (UFScar), Brasil

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-07-31
Completion
2028-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07134855 on ClinicalTrials.gov